TY - JOUR
T1 - Radiofrequency Ablation of Breast Cancer
T2 - A Retrospective Study
AU - Ito, Toshikazu
AU - Oura, Shoji
AU - Nagamine, Shinji
AU - Takahashi, Masato
AU - Yamamoto, Naohito
AU - Yamamichi, Noboru
AU - Earashi, Mitsuharu
AU - Doihara, Hiroyoshi
AU - Imoto, Shigeru
AU - Mitsuyama, Shoshu
AU - Akazawa, Kohei
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2018/8
Y1 - 2018/8
N2 - In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Combination of ultrasound-guided RFA of breast cancer with concurrent sentinel lymph node biopsy could potentially become state-of-the-art breast-conservative therapy for early breast cancer. Purpose: To validate the safety and efficacy of percutaneous radiofrequency ablation (RFA) of breast carcinomas. Methods: This retrospective study was conducted by the Breast Cancer Society for Minimally Invasive Therapy following approval from institutional review boards, and with the written informed consent of patients. A total of 386 patients with breast cancer treated with RFA at 10 institutions between July 2003 and June 2009 were identified and included in the analysis. Patients underwent a standard RFA procedure with ultrasound guidance and were followed up every 6 to 12 months. In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. Fisher exact or χ 2 test evaluated associations between clinicopathological factors and IBTR, and local recurrence-free survival was estimated using the Kaplan-Meier method. Results: RFA-related adverse events included local pain in 9 patients, skin burns in 15, and nipple retraction in 7. Patients were followed for a median of 50 months. IBTR was more frequently observed in patients with initial tumor sizes > 2 cm (3 of 30, 10%) than in those with initial tumors ≤ 2 cm (8 of 355, 2.3%; P =.015). IBTR-free rates 5 years after RFA were 97%, 94%, and 87% in patients with initial tumor sizes ≤ 1.0 cm, 1.1 to 2.0 cm, and > 2.0 cm, respectively. Conclusions: RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Further studies are needed to optimize the technique and evaluate its future role as local therapy.
AB - In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Combination of ultrasound-guided RFA of breast cancer with concurrent sentinel lymph node biopsy could potentially become state-of-the-art breast-conservative therapy for early breast cancer. Purpose: To validate the safety and efficacy of percutaneous radiofrequency ablation (RFA) of breast carcinomas. Methods: This retrospective study was conducted by the Breast Cancer Society for Minimally Invasive Therapy following approval from institutional review boards, and with the written informed consent of patients. A total of 386 patients with breast cancer treated with RFA at 10 institutions between July 2003 and June 2009 were identified and included in the analysis. Patients underwent a standard RFA procedure with ultrasound guidance and were followed up every 6 to 12 months. In this study, feasibility of RFA procedure and related safety and ipsilateral breast tumor recurrence (IBTR) were examined. Fisher exact or χ 2 test evaluated associations between clinicopathological factors and IBTR, and local recurrence-free survival was estimated using the Kaplan-Meier method. Results: RFA-related adverse events included local pain in 9 patients, skin burns in 15, and nipple retraction in 7. Patients were followed for a median of 50 months. IBTR was more frequently observed in patients with initial tumor sizes > 2 cm (3 of 30, 10%) than in those with initial tumors ≤ 2 cm (8 of 355, 2.3%; P =.015). IBTR-free rates 5 years after RFA were 97%, 94%, and 87% in patients with initial tumor sizes ≤ 1.0 cm, 1.1 to 2.0 cm, and > 2.0 cm, respectively. Conclusions: RFA in breast cancer is a safe and promising minimally invasive treatment for tumors ≤ 2 cm in diameter. Further studies are needed to optimize the technique and evaluate its future role as local therapy.
KW - Breast cancer
KW - Ipsilateral breast tumor recurrence
KW - Local therapy
KW - Minimally invasive surgical procedures
KW - Radiofrequency ablation
UR - http://www.scopus.com/inward/record.url?scp=85032205577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032205577&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2017.09.007
DO - 10.1016/j.clbc.2017.09.007
M3 - Article
C2 - 29079443
AN - SCOPUS:85032205577
SN - 1526-8209
VL - 18
SP - e495-e500
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 4
ER -
